Blog

Lilly’s $2.4B Bet on In…

Lilly’s $2.4B Bet on In…

ByAnuja Singh Mar 1, 2026

dummy-img

Could Amgen’s 340B Pricing Practices…

ByAnuja Singh Jan 24, 2026

dummy-img

Can Johnson & Johnson’s $550…

ByAnuja Singh Jan 24, 2026

dummy-img

Will Agios Pharma’s FDA Approval…

ByAnuja Singh Dec 26, 2025

dummy-img

How Will Bayer’s $1.3 Billion Bet…

ByAnuja Singh Aug 17, 2025

Image Not Found

Image Not Found

Categories

Gallery

Can Novo Nordisk’s AI Partnership with AWS Transform the Drug Discovery Timeline?

OmniAb and Eli Lilly Announce $370M Global Collaboration to Discover Antibody-Based Therapeutics Targeting Ion Channels

Sandoz’s $314M Bet on Chinese Biosimilars Targets a Drug the Industry Couldn’t Crack for a Decade

Merck and Moderna’s Melanoma Vaccine Win Could Be the Proof Point mRNA Oncology Has Been Waiting For

Prosper Medical’s $16M Raise Is a Bet That AI Can Make Concierge Medicine Affordable — Not Just Convenient

The FDA Just Created a Reimbursement Pathway for AI-Driven Care — Here’s Why That Matters More Than the Device, Dexcom the first participant in its TEMPO pilot.

GSK Bets on Cambridge: Inside the R&D Push Behind a £40 Billion Sales Target

Most-Favored-Nation Pricing: How U.S. Drug Prices Are Being Reset

Inside Medicare’s First Price Cuts: What a 38–79% Discount on 10 Blockbuster Drugs Means for Biopharma’s Next Decade